The National Cancer Institute, affiliated with the Academic Center for Education, Culture, and Research (ACECR), aims to establish a unified international structure. This structure is intended to unite the research, technological, clinical, educational, and economic potential of Islamic countries in the field of nanomedicine and cancer control, transforming it into a leading reference point in nanoncology within the Islamic world.
Zahra Sheikhi, Deputy of ACECR for Research and Technology, noted that one of the main objectives of the initiative is to create a center of innovation in nanoncology for Islamic countries. This center will be established in collaboration with the National Cancer Research Institute and a network of nanotechnology.
According to a statement from the ACECR website dated November 10, the institute officially joined the Inter-Islamic Network on Nanotechnology (INN) in November, paving the way for expanding scientific, research, and technological cooperation with 57 member states of this network.
The center will be responsible for guiding research projects, supporting technological developments, and conducting clinical trials in the field of nanomedicine.
Creating a Consortium and Developing Technologies
Sheikhi also added that there are plans to form a research consortium focused on anti-cancer nanomedicines. This consortium will rely on universities and research centers from member countries such as Turkey, Malaysia, Pakistan, and Egypt, under the scientific guidance of the National Cancer Research Institute.
Furthermore, the initiative includes launching an observatory for technologies and patents in the fight against cancer in the Islamic world. It also plans to create a common database for identifying and exchanging information on technologies, inventions, new compounds, and nanotechnology-based targeted therapy, which could promote the development of scientific capabilities of participating countries.
The initiative is also aimed at expanding sales markets for nanotechnology products manufactured by the institute in Islamic countries. These products include drug nanocarriers, nano-curcumin, peptides, nanotechnology-based diagnostic kits, nanosensors, and targeted drug delivery systems.
According to an official representative, several conditions are necessary to implement the initiative, including establishing a joint venture fund (VC) with the participation of foreign investors and philanthropists in the healthcare sector, especially from North African and Persian Gulf countries. Other key requirements include participation in international events, creating platforms for technology commercialization, strengthening research cooperation, developing joint scientific potential, establishing an International Academy of Nanomedicine and Cancer, developing an international accreditation system for nanoncology products, and enhancing medical diplomacy in the Islamic world.
Achievements in Improving Public Health
According to the October 2025 report, Motamed Cancer Institute, which has upgraded its status to Iranian National Cancer Institute, continues to achieve significant success in improving public health and well-being.
Ramin Sarrami-Foroushani, President of Motamed Cancer Institute, affiliated with ACECR, announced the elevation of the center's status to 'Iranian National Cancer Institute', calling it an important step in improving public health. He emphasized that ACECR, fulfilling its mission to address national problems and utilize scientific and technological potential, continues to make significant progress toward improving public health.
In this regard, a press conference was held on October 13th regarding Breast Cancer Awareness Month (October), where the Seventh National Campaign for Screening Common Cancers in Women was announced.
Sarrami-Foroushani reported that the center was officially elevated to the status of Iranian National Cancer Institute with the support of the ACECR Board of Directors, Central Headquarters, and Vice President for Research and Technology. He explained that under the umbrella of the National Cancer Research Institute, three specialized research centers will operate: the Research Institute of Regenerative Medicine and Advanced Cancer Treatment Methods, the Research Institute of Converging Technologies in Oncology, and the Research Institute of Personalized Medicine and Quality of Life, which collectively comprise about 10 research departments.
Sarrami-Foroushani added that this major achievement is the result of three decades of dedicated efforts by ACECR scientists and researchers, expressing hope that with continuous support from state bodies, the institute will become a leading national center for developing innovative cancer technologies.
In other remarks, Sarrami-Foroushani announced the start of construction of a 15-story tower for cancer innovation and advanced therapy ecosystem in Tehran. He specified that the project was initiated with strong support from Parliament, particularly the Health Commission, as well as the Organization for Planning and Budget and the Vice Presidency for Science, Technology, and Knowledge-Based Economy. Part of the funding has already been secured, and the upper floors of the tower will be allocated for the production of innovative technologies for advanced cancer treatment.
He specifically noted that maintaining the cultural identity of ACECR alongside technological development remains a key value of the institute. Adding: 'By focusing on innovation, we continue to integrate cultural principles into all our scientific and health-related initiatives—this is a distinguishing feature of the ACECR approach at Motamed Cancer Institute.'



